Review Cellular & Molecular Immunology (2013) 10, 303–310; doi:10.1038/cmi.2012.69; CCL5 as a potential immunotherapeutic target in triple-negative breast cancer Dandan Lv1, Yan Zhang2, Ha-Jeong Kim2, Lixing Zhang1 and Xiaojing Ma1,2 1Sheng Yushou Center of Cell Biology and Immunology, School of Life Science and Biotechnology, Shanghai Jiaotong University, Shanghai, China 2Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA Correspondence: Dr XJ Ma, Sheng Yushou Center of Cell Biology and Immunology, School of Life Science and Biotechnology, 800 Dongchuan Road, Shanghai Jiaotong University, Shanghai 20040, China. E-mail: [email protected] or E-mail: [email protected] Abstract Breast cancer (BC) is a leading cause of mortality among women in the world. To date, a number of molecules have been established as disease status indicators and therapeutic targets. The best known among them are estrogen receptor-α (ER-α), progesterone receptor (PR) and HER-2/neu. About 15%–20% BC patients do not respond effectively to therapies targeting these classes of tumor-promoting factors. Thus, additional targets are strongly and urgently sought after in therapy for human BCs negative for ER, PR and HER-2, the so-called triple-negative BC (TNBC). Recent clinical work has revealed that CC chemokine ligand 5 (CCL5) is strongly associated with the progression of BC, particularly TNBC. How CCL5 contributes to the development of TNBC is not well understood. Experimental animal studies have begun to address the mechanistic issue. In this article, we will review the clinical and laboratory work in this area that has led to our own hypothesis that targeting CCL5 in TNBCs will have favorable therapeutic outcomes with minimal adverse impact on the general physiology.
Posted on: Fri, 09 Aug 2013 12:37:32 +0000
Trending Topics
Recently Viewed Topics
© 2015